Immunotherapy

November 14, 2017

Forbes: Gilead-Kite: A Breakthrough. A $12 Billion Deal.

Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, made an expensive and gutsy move into the cutting edge of cancer treatment this […]